This is a preview of subscription content, log in via an institution to check access.
Notes
see PharmacoEconomics & Outcomes News 879 p34; 803564011
The highest US price a manufacturer should charge for a treatment, based on its improvement in overall health for patients, when a higher price would cause greater losses in health in other patients from rising costs of health care and insurance.
Reference
Institute for Clinical and Economic Review (ICER). ICER Publishes Evidence Report on Therapies for Atopic Dermatitis Internet Document : 13 Jul 2021. Available from: URL: https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-therapies-for-atopic-dermatitis/
Rights and permissions
About this article
Cite this article
ICER publishes evidence report on atopic dermatitis treatments. PharmacoEcon Outcomes News 883, 33 (2021). https://doi.org/10.1007/s40274-021-7904-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7904-8